A2i Therapeutics secures seed funding from FutuRx and its investors – Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority – to develop novel small molecule immuno-oncology agents.
A2i Therapeutics secures seed funding from FutuRx and its investors – Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority – to develop novel small molecule immuno-oncology agents. SAN FRANCISCO, CA and NESS ZIONA, Israel – December 18, 2020 – Atomwise, the leader in using artificial […]
Mark Terry of BioSpace reports on Atomwise’s three new joint ventures.
Connor Hale at FierceBiotech writes about Atomwise’s new joint ventures with SEngine Precision Medicine and OncoStatyx.